A bortezomib resistance–related gene signature predicts prognosis, with ARID5B downregulation associated with poor overall survival in multiple myeloma
The BRGs signature is a reliable biomarker for predicting the prognosis of MM and helps optimize clinical decision-making for treatment, and identifies key gene ARID5B downregulation as an adverse prognostic factor in multiple myeloma.
Authors
- Meng Xiao (ORCID: https://orcid.org/0000-0003-2103-7008)
- Jiajia Wang (ORCID: https://orcid.org/0000-0002-0554-1354)
- Xiong Shudao
- Xunyi Jiao
- Jinjing Guo
- Jinli Zhu
- Yangyang Ding
Institutions
- Fuyang Normal University (CN)
- Anhui Medical University (CN)
- Zhongda Hospital Southeast University (CN)
- The People's Hospital Tongling (CN)
- Jining First People's Hospital (CN)
- Second Affiliated Hospital of Anhui Medical University (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2026-01-06
- DOI
- https://doi.org/10.1007/s12672-026-04383-9
- Primary Topic
- Chromatin Remodeling and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00